Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Arends

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Orphanet Journal of Rare Diseases|June 17, 2015
Quality of life in patients with Fabry disease: a systematic review of the literatureMaarten Arends, Carla E M Hollak, Marieke Biegstraaten
Molecular Genetics and Metabolism|December 15, 2015
Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohortMaarten Arends, Gabor E Linthorst, Carla E Hollak, et al.
British Journal of Haematology|April 19, 2013
Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literatureMaarten Arends, Laura van Dussen, Marieke Biegstraaten, et al.
Drug Discovery Today|February 19, 2018
Adaptive pathway development for Fabry disease: a clinical approachYvonne Schuller, Maarten Arends, Simon Körver, et al.
Journal of Inherited Metabolic Disease|October 18, 2017
Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort studyMaarten Arends, Simon Körver, Derralynn A Hughes, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Molecular Genetics and Metabolism|May 13, 2017
Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry diseaseMaarten Arends, Frits A Wijburg, Christoph Wanner, et al.
Plos One|August 2, 2017
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsMaarten Arends, Marieke Biegstraaten, Derralynn A Hughes, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Orphanet Journal of Rare Diseases|June 17, 2015
Quality of life in patients with Fabry disease: a systematic review of the literatureMaarten Arends, Carla E M Hollak, Marieke Biegstraaten
Molecular Genetics and Metabolism|December 15, 2015
Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohortMaarten Arends, Gabor E Linthorst, Carla E Hollak, et al.
British Journal of Haematology|April 19, 2013
Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literatureMaarten Arends, Laura van Dussen, Marieke Biegstraaten, et al.
Drug Discovery Today|February 19, 2018
Adaptive pathway development for Fabry disease: a clinical approachYvonne Schuller, Maarten Arends, Simon Körver, et al.
Journal of Inherited Metabolic Disease|October 18, 2017
Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort studyMaarten Arends, Simon Körver, Derralynn A Hughes, et al.
Journal of the American Society of Nephrology : JASN|December 17, 2016
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter StudyMaarten Arends, Christoph Wanner, Derralynn Hughes, et al.
Molecular Genetics and Metabolism|May 13, 2017
Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry diseaseMaarten Arends, Frits A Wijburg, Christoph Wanner, et al.
Plos One|August 2, 2017
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsMaarten Arends, Marieke Biegstraaten, Derralynn A Hughes, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Pageof 1